OCTOPLUS ANNOUNCES LOCTERON STUDY RESULTS

A A

OctoPlus has reported the results of a Phase I study with Locteron, the company's controlled-release formulation of alfa interferon for the treatment of chronic hepatitis C.

Phase I results show that a single dose of Locteron delivered to healthy volunteers is safe and results supported that Locteron could be effectively dosed once every two weeks, which is a substantial improvement over the current pegylated interferons that require dosing every week

Locteron is designed to be a best-in-class therapeutic for patients with chronic hepatitis C, and has the potential to induce less side effects and to increase therapeutic efficacy and patient compliance compared with current therapies.